PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Triphala churna significantly reduced plasma glucose and oxidative stress parameters in diabetic rats [PMID:35168075]
Triphala churna mitigated diabetic neuropathy in rats, affecting parameters such as plasma glucose and motor nerve conduction velocity [PMID:34149415]
Triphala churna ameliorated nephropathy in rats by inhibiting TGF-β1 and oxidative stress [PMID:32674108]
Triphala churna demonstrated antifungal properties against Candida albicans on heat cure denture base material [PMID:28300045]
Triphala Churna (5gm daily) combined with Dadima Svarasa was used in a pilot study to manage high serum levels of copper, zinc, and lead [PMID:34690043]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 35168075 (2022) — Triphala churna ameliorates retinopathy in diabetic rats. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- 2.PMID: 34149415 (2021) — Triphala Churna-A Traditional Formulation in Ayurveda Mitigates Diabetic Neuropathy in Rats. · Frontiers in pharmacology
- 3.PMID: 23239004 (2012) — Scientific validation of the ethnomedicinal properties of the Ayurvedic drug Triphala: a review. · Chinese journal of integrative medicine
- 4.PMID: 22171288 (2011) — Antibacterial activity of some Indian Ayurvedic preparations against enteric bacterial pathogens. · Journal of advanced pharmaceutical technology & research
- 5.PMID: 32674108 (2020)